A5078158945- HIV/AIDS Research and Interventions
- HIV Research and Treatment
- HIV/AIDS drug development and treatment
- HIV-related health complications and treatments
- Pneumonia and Respiratory Infections
- Pneumocystis jirovecii pneumonia detection and treatment
- Mosquito-borne diseases and control
- Respiratory viral infections research
- Pharmacological Effects and Toxicity Studies
- Viral Infections and Vectors
- Adolescent Sexual and Reproductive Health
- Hepatitis B Virus Studies
- Influenza Virus Research Studies
- Bacterial Infections and Vaccines
- Malaria Research and Control
- SARS-CoV-2 and COVID-19 Research
- Poverty, Education, and Child Welfare
- Vaccine Coverage and Hesitancy
- Viral gastroenteritis research and epidemiology
- HIV, Drug Use, Sexual Risk
- Burkholderia infections and melioidosis
- Hepatitis C virus research
- Immunodeficiency and Autoimmune Disorders
- Adolescent and Pediatric Healthcare
- Dengue and Mosquito Control Research
Khon Kaen University
2016-2025
Siriraj Hospital
2019
Mahidol University
2019
Songklanagarind Hospital
2012-2018
Chulalongkorn University
2016-2017
National Institute of Allergy and Infectious Diseases
2012-2016
American Foundation for AIDS Research
2016
Eunice Kennedy Shriver National Institute of Child Health and Human Development
2016
Incorporated Research Institutions For Seismology
2016
Chiang Mai University
2016
Dengue, a mosquito-borne viral disease, was designated World Health Organization top 10 threat to global health in 2019.We present primary efficacy data from part 1 of an ongoing phase 3 randomized trial tetravalent dengue vaccine candidate (TAK-003) regions Asia and Latin America which the disease is endemic. Healthy children adolescents 4 16 years age were randomly assigned 2:1 ratio (stratified according category region) receive two doses or placebo months apart. Participants presenting...
Abstract Background Takeda’s live attenuated tetravalent dengue vaccine candidate (TAK-003) is under evaluation in a long-term clinical trial across 8 dengue-endemic countries. Previously, we have reported its efficacy and safety both seronegative seropositive participants that performance varies by serotype, with some decline from first to second year postvaccination. This exploratory analysis provides an update cumulative third-year data. Methods Healthy 4–16 olds (n = 20099) were...
Purpose: The study aimed to explore the prevalence and possible risk factors prevent face mask related adverse skin reactions during ongoing COVID-19 after a recommendation of wearing for public use in Thailand. Results: was 454 cases (54.5%), which acne most frequent (399; 39.9%), followed by rashes on (154; 18.4%), itch symptoms (130; 15.6%). Wearing surgical showed higher reaction compared cloth mask, OR (95% CI) = 1.54 (1.16-2.06). A duration more than 4 hours/day reuse masks increased...
BackgroundAbout half of the world's population lives in dengue-endemic areas. We aimed to evaluate long-term efficacy and safety two doses tetravalent dengue vaccine TAK-003 preventing symptomatic disease any severity due virus (DENV) serotypes children adolescents.MethodsIn this ongoing double-blind, randomised, placebo-controlled trial, we enrolled healthy participants aged 4–16 years at 26 medical research centres across eight countries (Brazil, Colombia, Dominican Republic, Nicaragua,...
We previously reported similar AIDS-free survival at 3 years in children who were >1 year old initiating antiretroviral therapy (ART) and randomized to early versus deferred ART the Pediatric Randomized Early Deferred Initiation Cambodia Thailand (PREDICT) study. now report neurodevelopmental outcomes.Two hundred eighty-four HIV-infected Thai Cambodian aged 1-12 with CD4 counts between 15% 24% no AIDS-defining illness initiate enrollment ("early," n = 139) or when count became <15% a Centers...
Takeda's dengue vaccine is under evaluation in an ongoing phase 3 efficacy study; we present a 2-year update.Children (20 099, 4-16 years old) were randomized to receive 2 doses of TAK-003 or placebo months apart and are surveillance detect by serotype-specific RT-PCR.Cumulative against approximately 27 since first dose was 72.7% (95% confidence interval [CI], 67.1%-77.3%), including 67.0% CI, 53.6%-76.5%) dengue-naive 89.2% 82.4%-93.3%) hospitalized dengue. In the second year, decline...
Abstract Background We explored the impact of prior yellow fever (YF) or Japanese encephalitis (JE) vaccination on efficacy Takeda's dengue vaccine candidate, TAK-003. Methods Children 4–16 years age were randomized 2:1 to receive TAK-003 placebo and under active febrile surveillance. Symptomatic was confirmed by serotype-specific reverse-transcription polymerase chain reaction. YF JE history recorded. Results Of 20 071 children who received placebo, 21.1% had a 23.9% at randomization....
Human immunodeficiency virus (HIV)-negative children born to HIV-infected mothers may exhibit differences in neurodevelopment (ND) compared age- and gender-matched controls whose lives have not been affected by HIV. This could occur due exposure HIV antiretroviral agents utero perinatally, or the environment which they grow up. study assessed neurodevelopmental outcomes HIV-exposed uninfected (HEU) HIV-unexposed (HUU) enrolled as a multicenter ND from Thailand Cambodia. One hundred sixty HEU...
ABSTRACT We examined whether human immunodeficiency virus type 1 (HIV-1) fitness was altered upon the acquisition of a set or subset five mutations (A62V, V75I, F77L, F116Y, and Q151M) in pol gene, which confers resistance to multiple dideoxynucleosides (MDR), as well zidovudine resistance-associated mutation T215Y, using competitive HIV-1 replication assay setting an HXB2D genetic background. Target H9 cells were exposed 50:50 mixture paired infectious molecular clones, culture supernatant...
Mitochondrial toxicity is a major adverse effect of the nucleoside reverse-transcriptase inhibitors (NRTIs) used for treatment human immunodeficiency virus type 1 (HIV-1) infection and can result in life-threatening lactic acidosis. The due to inhibition polymerase gamma (Pol gamma), which required replication mitochondrial DNA (mtDNA). Genetic factors could be involved this process, given that not all NRTI-treated patients experience toxicity. In patient with acidosis, novel homozygous Pol...
Purpose: This study aimed to explore the prevalence of and possible risk factors for hand eczema with respect dissemination information about new hygiene habits protect against ongoing COVID-19 cross-transmission. The authors conducted a survey among health care workers (HCWs) non-HCW populations in Khon Kaen, Thailand. Results: A total 805 participants participated. population was 20.87%. There were several factors, including working as HCW, having history previous eczema, underlying atopic...
To assess a new, fully-liquid, hexavalent DTaP-IPV-Hep B-PRP-T vaccine (diphtheria toxoid (D), tetanus (T), acellular pertussis (aP), inactivated poliovirus (IPV), hepatitis B (Hep B), and Haemophilus influenzae type b polysaccharide conjugated to protein (PRP-T) antigens) compared licensed B//PRP-T following primary series co-administration with 7-valent pneumococcal conjugate (PCV7).This was randomized, phase III, observer-blind study in Thai infants (N=412), who received or at 2, 4, 6...
This trial in 1200 JE-vaccination naïve children (age 12–18 mo) Thailand and the Philippines aimed to demonstrate consistency of three successive industrial scale manufacturing lots live attenuated Japanese encephalitis chimeric virus vaccine (JE-CV) between a fourth, development lot. Children received JE-CV from one produced (n = 899), or fourth lot USA 199), hepatitis A control 102). Antibodies were assessed by 50% plaque reduction neutralization test (PRNT50) at screening Day 28....
There are limited data of immunologic and virologic failure in Asian HIV-infected children using non-nucleoside reverse transcriptase inhibitor (NNRTI)-based highly active antiretroviral therapy (HAART). We examined the incidence rate (IF) (VF) accuracy IF to predict VF Thai first-line NNRTI-based HAART.Antiretroviral (ART)-naïve from 2 prospective cohorts treated with HAART during 2001-2008 were included. CD4 counts performed every 12 weeks plasma HIV-RNA measured 24 weeks. Immune recovery...
We conducted a prospective monitoring study to determine whether antiretroviral (ARV) levels in hair of Asian children on second-line protease inhibitor-based ARV therapy (ART) are associated with virologic failure (VF), compared plasma drug and self-reported adherence. HIV-infected ART regimens were enrolled into longitudinal cohort. Traditional adherence measures, plasma, samples collected 24 weeks after enrollment. Hair determined via liquid chromatography/tandem mass spectrometry. Among...
A 9-valent human papillomavirus (9vHPV) vaccine has recently been reported to be safe and highly efficacious against infection disease related HPV6/11/16/18/31/33/45/52/58. We evaluated the immunogenicity safety of 9vHPV administered concomitantly with REPEVAX (diphtheria, tetanus, acellular pertussis inactivated poliomyelitis vaccine).This open-label, randomized, multicenter study enrolled 1054 males females ages 11-15 years. Subjects were randomly assigned each group in a 1:1 ratio....
Background: We evaluated an inactivated quadrivalent influenza vaccine (IIV4) in children 6–35 months of age a phase III, observer-blind trial. Methods: The aim this analysis was to estimate efficacy (VE) preventing laboratory-confirmed each 5 independent seasonal cohorts (2011−2014), as well impact on healthcare utilization 3 study regions (Europe/Mediterranean, Asia-Pacific and Central America). Healthy were randomized 1:1 IIV4 or control vaccines. VE estimated against confirmed by reverse...
Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) was efficacious and well tolerated in children/adolescents with HIV (aged ≥6 years, weighing ≥25 kg) a Phase 2/3 study. Here, we report data from children aged ≥2 years ≥14-<25 kg. This is an analysis of the youngest cohort open-label, multicentre, multi-cohort, single-group, international study HIV. Participants this were kg at screening able to swallow tablets, on stable antiretroviral therapy virologic suppression...